6 citations
,
May 2023 in “Molecules” In this study, dry powder inhalers containing Cepharanthine were administered to rats with acute lung injury, significantly reducing pulmonary edema, hemorrhage, and inflammatory markers, suggesting its potential as an effective anti-inflammatory treatment when inhaled directly into the lungs.
45 citations
,
January 2021 in “Drug Delivery” In this study, researchers developed a biomimetic anti-inflammatory nanosystem (MM-CEP/NLCs) that significantly reduced the severity of acute lung injury in vivo by targeting and accumulating in lung inflammation sites, showcasing its potential for treating inflammation.
14 citations
,
April 2022 in “Molecules” This study found that pulmonary delivery of cepharanthine significantly improved bioavailability and may provide protective effects against pulmonary fibrosis related to COVID-19 infection in a rat model.
1 citations
,
January 2020 In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” This study demonstrated that CEP may effectively treat pulmonary fibrosis by inhibiting fibroblast activation through regulating macrophage M2 polarization and decreasing fibrosis-associated factors, suggesting a new avenue for future research in this area.
